The FDA approved Xdemvy, a 0.25% lotilaner ophthalmic solution, for the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.
“The approval of Xdemvy represents a new solution that eye care providers will have in their toolbox to manage patients with Demodex blepharitis,” Aziz Mottiwala, chief commercial officer at Tarsus, told Healio. “Xdemvy significantly improves eyelids in terms of collarette reduction, cures erythema and eradicates mites — the primary cause of the disease.”
Xdemvy, formerly known as TP-03, is the first